Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction.
Azin AlizadehaslMina MohseniKamran RoudiniParisa FiroozbakhshPublished in: Cardio-oncology (London, England) (2024)
Treatment with trastuzumab seems to be safe in patients with pre-existing LVSD (LVEF = 40-53%). Such high-risk patients should be strictly monitored and cardiovascular risk factors, such as HTN should be regulated.
Keyphrases
- cardiovascular risk factors
- left ventricular
- end stage renal disease
- heart failure
- ejection fraction
- epidermal growth factor receptor
- chronic kidney disease
- newly diagnosed
- blood pressure
- cardiovascular disease
- metabolic syndrome
- peritoneal dialysis
- prognostic factors
- acute myocardial infarction
- aortic stenosis
- oxidative stress
- transcription factor
- type diabetes
- metastatic breast cancer
- atrial fibrillation
- acute coronary syndrome
- coronary artery disease
- cardiac resynchronization therapy
- percutaneous coronary intervention
- smoking cessation